• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Twelve-month outcomes of 400 patients treated with a resorbable metal scaffold: insights from the BIOSOLVE-IV registry.

作者信息

Verheye Stefan, Wlodarczak Adrian, Montorsi Piero, Bennett Johan, Torzewski Jan, Haude Michael, Vrolix Mathias, Buck Thomas, Aminian Adel, van der Schaaf Rene J, Nuruddin Amin Arrif, Lee Michael K Y

机构信息

Interventional Cardiology, ZNA Cardiovascular Center Middelheim, Antwerp, Belgium.

出版信息

EuroIntervention. 2020 Feb 7;15(15):e1383-e1386. doi: 10.4244/EIJ-D-18-01058.

DOI:10.4244/EIJ-D-18-01058
PMID:30666963
Abstract
摘要

相似文献

1
Twelve-month outcomes of 400 patients treated with a resorbable metal scaffold: insights from the BIOSOLVE-IV registry.
EuroIntervention. 2020 Feb 7;15(15):e1383-e1386. doi: 10.4244/EIJ-D-18-01058.
2
Sustained safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de novo coronary lesions: 12-month clinical results and angiographic findings of the BIOSOLVE-II first-in-man trial.第二代药物洗脱可吸收金属支架在初发冠状动脉病变患者中的持续安全性和性能：BIOSOLVE-II首次人体试验的12个月临床结果和血管造影结果
Eur Heart J. 2016 Sep 14;37(35):2701-9. doi: 10.1093/eurheartj/ehw196. Epub 2016 May 17.
3
Sustained safety and clinical performance of a drug-eluting absorbable metal scaffold up to 24 months: pooled outcomes of BIOSOLVE-II and BIOSOLVE-III.药物洗脱可吸收金属支架 24 个月的持续安全性和临床疗效：BIOSOLVE-II 和 BIOSOLVE-III 的汇总结果。
EuroIntervention. 2017 Jul 20;13(4):432-439. doi: 10.4244/EIJ-D-17-00254.
4
Safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de-novo coronary artery lesions (BIOSOLVE-II): 6 month results of a prospective, multicentre, non-randomised, first-in-man trial.第二代药物洗脱可吸收金属支架在初发冠状动脉病变患者中的安全性和性能（BIOSOLVE-II）：前瞻性、多中心、非随机、首例人体试验的 6 个月结果。
Lancet. 2016 Jan 2;387(10013):31-9. doi: 10.1016/S0140-6736(15)00447-X. Epub 2015 Oct 12.
5
In vivo serial invasive imaging of the second-generation drug-eluting absorbable metal scaffold (Magmaris - DREAMS 2G) in de novo coronary lesions: Insights from the BIOSOLVE-II First-In-Man Trial.在体连续侵袭性成像第二代药物洗脱可吸收金属支架（Magmaris - DREAMS 2G）在初发冠状动脉病变中的应用：来自 BIOSOLVE-II 首次人体试验的结果。
Int J Cardiol. 2018 Mar 15;255:22-28. doi: 10.1016/j.ijcard.2017.12.053. Epub 2017 Dec 28.
6
Safety and performance of the DRug-Eluting Absorbable Metal Scaffold (DREAMS) in patients with de novo coronary lesions: 3-year results of the prospective, multicentre, first-in-man BIOSOLVE-I trial.药物洗脱可吸收金属支架（DREAMS）在初发冠状动脉病变患者中的安全性和性能：前瞻性、多中心、人体首例BIOSOLVE-I试验的3年结果
EuroIntervention. 2016 Jun 12;12(2):e160-6. doi: 10.4244/EIJ-D-15-00371.
7
The BIOSOLVE II trial: a step forward for the bioresorbable scaffold?BIOSOLVE II试验：生物可吸收支架向前迈进的一步？
Eur Heart J. 2016 Sep 14;37(35):2710-2. doi: 10.1093/eurheartj/ehw227. Epub 2016 Jun 26.
8
First Report of Edge Vascular Response at 12 Months of Magmaris, A Second-Generation Drug-Eluting Resorbable Magnesium Scaffold, Assessed by Grayscale Intravascular Ultrasound, Virtual Histology, and Optical Coherence Tomography. A Biosolve-II Trial Sub-Study.通过灰阶血管内超声、虚拟组织学和光学相干断层扫描评估的第二代药物洗脱可吸收镁支架Magmaris在12个月时边缘血管反应的首次报告。一项Biosolve-II试验子研究。
Cardiovasc Revasc Med. 2019 May;20(5):392-398. doi: 10.1016/j.carrev.2019.02.019. Epub 2019 Feb 18.
9
Hybrid metal/scaffold-jacket versus full-metal jackets in left anterior descending coronary artery diffuse disease: Differences in radiation exposure and fluoroscopic/procedural times.杂交金属/支架外套与全金属外套用于左前降支冠状动脉弥漫性疾病：辐射暴露及透视/手术时间的差异
Cardiovasc Revasc Med. 2017 Dec;18(8):592-595. doi: 10.1016/j.carrev.2017.05.015. Epub 2017 May 18.
10
Evaluation of the short- and long-term safety and therapy outcomes of the everolimus-eluting bioresorbable vascular scaffold system in patients with coronary artery stenosis: Rationale and design of the German-Austrian ABSORB RegIstRy (GABI-R).依维莫司洗脱生物可吸收血管支架系统治疗冠状动脉狭窄患者的短期和长期安全性及治疗效果评估：德国-奥地利生物可吸收支架注册研究（GABI-R）的原理与设计
Cardiovasc Revasc Med. 2016 Jan-Feb;17(1):34-7. doi: 10.1016/j.carrev.2015.09.002. Epub 2015 Sep 10.

引用本文的文献

1
Progress in research and development of biodegradable metallic vascular stents.可生物降解金属血管支架的研发进展
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2024 Nov 28;49(11):1861-1868. doi: 10.11817/j.issn.1672-7347.2024.230514.
2
Bioresorbable Magnesium-Based Stent: Real-World Clinical Experience and Feasibility of Follow-Up by Coronary Computed Tomography: A New Window to Look at New Scaffolds.生物可吸收镁基支架：真实世界临床经验及冠状动脉计算机断层扫描随访的可行性：观察新型支架的新窗口
Biomedicines. 2023 Apr 11;11(4):1150. doi: 10.3390/biomedicines11041150.
3
Magnesium Bioresorbable Scaffold (BRS) Magmaris vs Biodegradable Polymer DES Ultimaster in NSTE-ACS Population-12-Month Clinical Outcome.
镁可吸收支架（BRS） Magmaris 与生物可降解聚合物 DES Ultimaster 在 NSTE-ACS 人群中的 12 个月临床结局比较。
J Interv Cardiol. 2022 Dec 20;2022:5223317. doi: 10.1155/2022/5223317. eCollection 2022.
4
[Future of interventional cardiology : Does everything revolve around AI and robotics?].
Herz. 2022 Dec;47(6):518-523. doi: 10.1007/s00059-022-05146-2. Epub 2022 Oct 28.
5
Mg-based materials diminish tumor spreading and cancer metastases.镁基材料可减少肿瘤扩散和癌症转移。
Bioact Mater. 2022 May 10;19:594-610. doi: 10.1016/j.bioactmat.2022.05.002. eCollection 2023 Jan.
6
Effect of silver in thermal treatments of Fe-Mn-C degradable metals: Implications for stent processing.银在Fe-Mn-C可降解金属热处理中的作用：对支架加工的启示。
Bioact Mater. 2021 Oct 21;12:30-41. doi: 10.1016/j.bioactmat.2021.10.020. eCollection 2022 Jun.
7
Biodegradable Polymer DES (Ultimaster) vs. Magnesium Bioresorbable Scaffold (BRS Magmaris) in Diabetic Population with NSTE-ACS: A One-Year Clinical Outcome of Two Sirolimus-Eluting Stents.可生物降解聚合物 DES（Ultimaster）与镁生物可吸收支架（BRS Magmaris）在合并糖尿病的 NSTE-ACS 患者中的比较：两种西罗莫司洗脱支架的一年临床结局。
J Diabetes Res. 2021 Nov 23;2021:8636050. doi: 10.1155/2021/8636050. eCollection 2021.
8
Bioresorbable Scaffolds: Contemporary Status and Future Directions.生物可吸收支架：现状与未来方向
Front Cardiovasc Med. 2020 Nov 30;7:589571. doi: 10.3389/fcvm.2020.589571. eCollection 2020.
9
BIOSOLVE-IV-registry: Safety and performance of the Magmaris scaffold: 12-month outcomes of the first cohort of 1,075 patients.BIOSOLVE-IV 注册研究：Magmaris 支架的安全性和性能：1075 例患者的首个队列 12 个月结果。
Catheter Cardiovasc Interv. 2021 Jul 1;98(1):E1-E8. doi: 10.1002/ccd.29260. Epub 2020 Sep 3.
10
Are we curing one evil with another? A translational approach targeting the role of neoatherosclerosis in late stent failure.我们是否在以一种弊端治疗另一种弊端？一种针对新生动脉粥样硬化在晚期支架失败中作用的转化医学方法。
Eur Heart J Suppl. 2020 Apr;22(Suppl C):C15-C25. doi: 10.1093/eurheartj/suaa006. Epub 2020 Apr 29.